Overview

Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of alogliptin, once daily (QD), taken in combination with insulin for the treatment of Type 2 Diabetes.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Alogliptin
Insulin
Insulin, Globin Zinc